

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Jacobson Pharma Corporation Limited**

**雅各臣科研製藥有限公司**

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

### **MAJOR TRANSACTION WRITTEN SHAREHOLDERS' APPROVAL UNDER RULE 14.44**

Reference is made to the announcement of Jacobson Pharma Corporation Limited (the “**Company**”) dated December 13, 2016 (the “**Announcement**”) in relation to the acquisition of the entire share capital of Victor Luck Limited and Happy Echo Limited respectively. Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As the Acquisition constitutes a major transaction of the Company under Chapter 14 of the Listing Rules, it is subject to the reporting, announcement, circular and shareholders’ approval requirements under Chapter 14 of the Listing Rules.

Pursuant to Rule 14.44 of the Listing Rules, in lieu of holding a general meeting, the Company has obtained written shareholders’ approval from Kingshill, a Shareholder which is holding 850,684,000 Shares, and Longjin, a Shareholder which is holding 157,050,000 Shares. Kingshill and Longjin in aggregate hold 1,007,734,000 Shares, representing approximately 55.50% of the total number of the issued Shares as at the date of this announcement.

Pursuant to Rule 14.41(a) of the Listing Rules, a circular containing, amongst other things, information in relation to the Sale and Purchase Agreement and the transactions contemplated thereunder (the “**Circular**”), is required to be despatched to the Shareholders for their information within 15 business days after the publication of the Announcement, which is on or before January 5, 2017. As disclosed in the Announcement, since the Company requires additional time to prepare and finalise the necessary information for inclusion in the Circular, the Company intends to apply to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules to delay the despatch of the Circular.

By Order of the Board  
**Jacobson Pharma Corporation Limited**  
**Wong Wai Ming**  
*Company Secretary*

Hong Kong, December 14, 2016

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chief Executive Officer), Mr. Lo Chun Bun and Mr. Yim Chun Leung as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Professor Chow Hee Lum, Albert, Dr. Lam Kwing Tong, Alan and Mr. Young Chun Man, Kenneth as independent non-executive Directors.*